Evidence map›Paper›PMID 39018897›Full record

ArticleJournal of diabetes and its complications2024

Dipeptidyl peptidase 4 inhibitors, sodium glucose cotransporter 2 inhibitors, and glucagon-like peptide 1 receptor agonists do not worsen diabetic macular edema.

Alexander Phu, Mark Banghart, Mozhdeh Bahrainian, T Y Alvin Liu, Risa M Wolf, Roomasa Channa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes and its complications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alexander PhuDepartment of Medicine, Kansas City University, Kansas City, MO, USA.
Mark BanghartDepartment of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, WI, USA.
Mozhdeh BahrainianDepartment of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, WI, USA.
T Y Alvin LiuWilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA.
Risa M WolfDepartment of Pediatrics, Division of Endocrinology, Johns Hopkins Medicine, Baltimore, MD, USA.
Roomasa ChannaDepartment of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, WI, USA. Electronic address: rchanna@wisc.edu.

Funding

NEI NIH HHS K23 EY030911NEI NIH HHS R01 EY033233
6 · The paper itself

Abstract

aimsThere are limited studies on dipeptidyl-peptidase 4 inhibitor (DPP-4i), sodium glucose cotransporter 2 inhibitor (SGLT2-i), and glucagon-like peptide 1 (GLP-1) receptor agonist use and occurrence of diabetic macular edema (DME). The objective of this study was to determine the association between DPP-4i, SGLT2-i, and GLP-1 receptor agonist use and occurrence of DME.

methodsProportional hazard models were used to evaluate the change in hazard of developing DME associated with DPP-4i, SGLT2-i, or GLP-1 receptor agonist use. Models accounted for age at DR diagnosis, DR severity (proliferative vs non-proliferative stage), time-weighted average of HbA1c level, sex, and self-reported race/ethnicity. A p-value ≤ 0.05 was considered statistically significant.

resultsThe hazard ratio of developing DME after diagnosis of DR was 1.2 (CI = 0.75 to 1.99; p = 0.43) for DPP-4i use, 0.93 (CI = 0.54 to 1.61; p = 0.81) for GLP-1 receptor agonist use, 0.82 (CI = 0.20 to 3.34; p = 0.78) for SGLT2-i use, 1.1 (CI = 0.75 to 1.59; p = 0.66) for any one medication use, 1.1 (CI = 0.62 to 2.09; p = 0.68) and for any two or more medications use.

conclusionsWe did not find an association between DPP-4i, SGLT2-i, or GLP-1 receptor agonist use and increased hazard of development of DME among patients with DR.

Indexed as

Diabetes Mellitus, Type 2Diabetic RetinopathyDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsMacular EdemaSodium-Glucose Transporter 2 InhibitorsAgedCohort StudiesFemaleHumansHypoglycemic AgentsMaleMiddle AgedDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsDiabetic macular edemaDipeptidyl-peptidase 4 inhibitorGlucagon-like peptide 1Sodium glucose cotransporter 2 inhibitor

Identifiers

PMID39018897
PMCPMC11315198

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.